FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						Secu	011 30(	11) 01 1116	e investine		ompany Act	01 1940								
1. Name and Address of Reporting Person* Fisher Stewart						2. Issuer Name and Ticker or Trading Symbol C4 Therapeutics, Inc. [ CCCC ]  3. Date of Earliest Transaction (Month/Day/Year) 12/11/2020									5. Relationship of Reporting Person(s) to Issue (Check all applicable)  Director 10% Own  X Officer (give title Other (spe					
	C/O C4 THERAPEUTICS, INC.														Officer (give title Other below) below  Chief Scientific Officer			(specify )		
490 ARSENAL WAY #200					_ 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street)															Line)  X Form filed by One Reporting Person					
WAIEK	WATERTOWN MA 02472				_										Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)											1 013	OII					
		Tab	le I - No	n-Deriv	/ative	e Se	curit	ies A	cquired	, Di	sposed (	of, or Be	nefici	ally Own	ed					
(, (			2. Transaction Date (Month/Day/Year		Execution Date,		, Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 an		nd Secur Benef Owne	Beneficially Owned Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount	Amount (A) or (D)		Trans	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common	Stock			12/1	1/2020				М		4,74	3 A	\$2	.11 9	90,115		D			
Common Stock			12/1	1/2020				М		9,70	1 A	\$3.	71 <sup>(1)</sup>	9,816		D				
Common Stock				02/03	03/2021				M		2,37	1 A	\$2	.11 1	2,187		D			
Common Stock			02/03	3/2021				M		5,92	9 A	\$3.	71(1) 1	08,116		D				
		1												ly Owned	I					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deeme Execution if any (Month/Da	ed Date,	4. Transaction Code (Instr. 8)		n of		6. Date E	6. Date Exercisa Expiration Date (Month/Day/Year		7. Title an Amount of Securities Underlyin Derivative (Instr. 3 a	d f s g Securit	8. Price of Derivative Security (Instr. 5)		e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amour or Number of Shares	er						
Stock Option (Right to Buy)	\$2.11	12/11/2020			M			4,743	(2)		07/12/2026	Common Stock	4,743	\$0.00	4,742	2	D			
Stock Option (Right to Buy)	\$3.71 <sup>(1)</sup>	12/11/2020			M			9,701	(3)		04/23/2028	Common Stock	9,70	\$0.00	61,44.	3	D			
Stock Option (Right to Buy)	\$2.11	02/03/2021			M			2,371	(2)		07/12/2026	Common Stock	2,371	\$0.00	2,371	l	D			
Stock Option (Right to Buy)	\$3.71 <sup>(1)</sup>	02/03/2021			M			5,929	(3)		04/23/2028	Common Stock	5,929	\$0.00	55,51	4	D			

## **Explanation of Responses:**

- 1. The Form 3 filed on October 1, 2020 included an incorrect exercise price in Table II, Column 2 (\$3.72).
- 2. Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 20% of this option vested and became exercisable on May 2, 2017, with the remainder vesting in 16 equal quarterly installments thereafter.
- 3. Represents underlying unexercised stock options that were granted on April 24, 2018. The terms of the original grant provide that 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter.

## Remarks:

/s/ Jolie M. Siegel, Attorneyin-Fact

02/04/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.